NEW YORK, Aug. 1-The chemical proteomics firm ActivX Biosciences won a $155,000 Small Business Innovation Research grant for its toxicology research program, the company said today.
The grant, awarded by the National Cancer Institute, will fund six months of research. ActivX plans to investigate proteins as markers for toxicity. After identifying a set of proteins associated with toxic response, ActivX will create profiles that can be used to evaluate compounds for pharmaceutical development.
This award is the company's first SBIR grant. ActivX intends to apply for a Phase II SBIR grant to extend this research.
ActivX is a privately held firm in La Jolla, Calif.